Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Urinary Bladder Neoplasms
Interventions: nivolumab, Placebo, Bacillus Calmette-Guérin (BCG); Drug · Other · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois • The Bronx, New York

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more

Conditions: Healthy
Interventions: Placebo, LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Epilepsy
Interventions: OPC-214870, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ormond Beach, Florida

Conditions: Healthy Volunteers
Interventions: NPT520-34 (125 mg), Placebos (125 mg); Drug
Lead sponsor: Neuropore Therapies Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Exercise Performance of Fit Athletes, Exercise Performance, Cycling Performance
Interventions: Dietary Nitrate, Caffeine, Placebo; Dietary Supplement · Other
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteer, Psoriasis
Interventions: ABBV-547, ABBV-547 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Acute Pain
Interventions: Placebos, Lorazepam; Drug
Lead sponsor: Maria Pacella; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: LIB003; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteer
Interventions: Placebo, PF-04958242; Drug
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions: Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo; Other · Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Anaemia
Interventions: Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157 or Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Asthma
Interventions: PF-04191834, zileuton, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • North Dartmouth, Massachusetts • Kalamazoo, Michigan + 1 more

Conditions: Odontalgia, Toothache
Interventions: Epidiolex 100 mg/mL Oral Solution, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Proliferative Diabetic Retinopathy
Interventions: emixustat hydrochloride, Placebo; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Gout
Interventions: RDEA3170 and Placebo; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subjects
Interventions: AZD1979, Placebo to match; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: West Nile Viral Infection
Interventions: HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure
Interventions: Mesenchymal Precursor cells (RevascorTM), Cryoprotective media alone; Biological · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: San Diego, California • Washington D.C., District of Columbia • Oak Lawn, Illinois + 12 more

Search by objective public record fields.

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

A Study of LY3039478 in Healthy Participants

A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

Effect of the Combination of Nitrate and Caffeine on Critical Power In Trained Male Cyclists

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Benzodiazepines for the Reduction of Distress and Pain During and After Emergency Department Care

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

A Study Of PF-05175157 In Healthy Volunteers

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

CBD for Dental Pain

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Single and Multiple Dose Study in Japanese Subjects

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD